---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-26-074678"
form_type: "8-K"
ticker: "UNCY"
cik: "0001766140"
company_name: "Unicycive Therapeutics, Inc."
filed_at: "2026-07-02T14:30:00+00:00"
generated_at: "2026-07-02T14:31:05.259849+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Unicycive Therapeutics reports preliminary Q2 2026 cash balance of $61.4M

## Summary
- Ending cash balance of approximately $61.4 million as of June 30, 2026.
- Preliminary, unaudited results for the second quarter ended June 30, 2026.
- No other financial details or comparisons provided in the filing.

## SEC filing metadata
- accession: 0001213900-26-074678
- form_type: 8-K
- ticker: UNCY
- cik: 0001766140
- company_name: Unicycive Therapeutics, Inc.
- filed_at: 2026-07-02T14:30:00+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1766140/000121390026074678/0001213900-26-074678-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1766140/000121390026074678/ea0296892-8k_unicycive.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-26-074678
- JSON: https://secwatch.observer/filing/0001213900-26-074678.json
- Plain text: https://secwatch.observer/filing/0001213900-26-074678.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.